Valion Bio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Valion Bio, Inc. (VBIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 45.00 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-14
- Valion Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 45.00K shares.
- Valion Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 0.00 shares.
- Valion Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 54.00K shares.
- Valion Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 342.50K shares, a 2754.17% increase year-over-year.
- Valion Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 400.50K shares, a 4833.48% increase from fiscal 2024.
- Valion Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 8.12K shares, a 2294.69% increase from fiscal 2023.
- Valion Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 339.00 shares, a 95.40% decline from fiscal 2022.
- Valion Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 7.37K shares, a 97.37% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 45.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | 45.00K shares 10-Q · filed 2026-08-14 | 99.00K shares derived: sum of 3 quarters · filed 2026-08-14 | 441.50K shares derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-14 | 54.00K shares derived: sum of 2 quarters · filed 2026-05-14 | 396.50K shares derived: sum of 3 quarters · filed 2026-05-14 | ||
| 2025-12-31 | 54.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 396.50K shares derived: sum of 2 quarters · filed 2026-03-30 | 400.50K shares 10-K · filed 2026-03-30 | ||
| 2025-09-30 | 342.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | 346.50K shares 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | 4.00K shares 10-Q · filed 2025-08-14 | ||||
| 2024-12-31 | -45.88K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -33.88K shares derived: sum of 2 quarters · filed 2026-03-30 | -33.88K shares derived: sum of 3 quarters · filed 2026-03-30 | 8.12K shares 10-K · filed 2026-03-30 | |
| 2024-09-30 | 12.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 12.00K shares derived: sum of 2 quarters · filed 2024-11-14 | 54.00K shares 10-Q · filed 2024-11-14 | 48.59K shares derived: sum of 4 quarters · filed 2025-03-21 | |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 42.00K shares 10-Q · filed 2024-08-14 | 36.59K shares derived: sum of 3 quarters · filed 2025-03-21 | -532.66K shares derived: sum of 4 quarters · filed 2025-03-21 | |
| 2024-03-31 | 42.00K shares 10-Q · filed 2024-05-15 | 36.59K shares derived: sum of 2 quarters · filed 2025-03-21 | -532.66K shares derived: sum of 3 quarters · filed 2025-03-21 | ||
| 2023-12-31 | -5.41K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | -574.66K shares derived: sum of 2 quarters · filed 2025-03-21 | 339.00 shares 10-K · filed 2025-03-21 | 5.75K shares 10-K · filed 2024-03-25 | |
| 2023-09-30 | -569.25K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 5.75K shares 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | 575.00K shares 10-Q · filed 2023-08-14 | ||||
| 2022-12-31 | -709.26K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -689.26K shares derived: sum of 2 quarters · filed 2024-03-25 | -436.38K shares derived: sum of 3 quarters · filed 2024-03-25 | 7.37K shares 10-K · filed 2024-03-25 | 736.63K shares 10-K · filed 2023-03-31 |
| 2022-09-30 | 20.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 272.88K shares derived: sum of 2 quarters · filed 2022-11-14 | 716.63K shares 10-Q · filed 2022-11-14 | ||
| 2022-06-30 | 252.88K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 696.63K shares 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | 443.75K shares 10-Q · filed 2022-05-16 | ||||
| 2021-12-31 | 280.25K shares 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |